Medicine

Entecavir for Hepatitis B Linked to HIV Resistance

Moira McMahon
Moira McMahon

REFERENCE:47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Chicago, 2007
MOIRA MCMAHON, Johns Hopkins University, Baltimore
The hepatitis B drug entecavir appears to select for a drug resistant HIV mutation – and this has implications for patients infected with both viruses. Derek Thorne got the details from Moira McMahon from Johns Hopkins University in Baltimore. .

Similar Interviews

  • Entecavir Shows Activity Against HIV But Also Selects for an Antiretroviral Drug Resistance Mutation
  • CHLOE THIO, Johns Hopkins University School of Medicine REFERENCE: Abstract: 136LB, 14th Conference on Retroviruses and Opportunistic Infections, Los Angeles February

  • Shorter Anti-Viral Treatment for Hepatitis C: Less Effective Than Standard Regimen
  • Mitchell Shiffman REFERENCE: N Engl J Med 2007;357:124-34 MITCHELL SHIFFMAN, Virginia Commonwealth University, Richmond Standard anti-viral therapy for Hepatitis

  • Which HIV Treatment is Best for Patients with HIV and Hepatitis C?
  • Juan Berenguer REFERENCE: Abstract V-1385, 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Chicago, 2007

    Post a comment

    Subscribe to Audio Medica Podcast